Foslevodopa is a medication which acts as a prodrug for levodopa, originally invented in the 1980s but not developed for medical use at that time.[1] It is approved for use in a subcutaneous infusion as a fixed-dose combination with foscarbidopa for the treatment of Parkinson's disease, under the brand name Vyalev.[2][3]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H12NO7P |
| Molar mass | 277.169 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
edit- ^ Agin PP, Sayre RM, Pawelek JM (1987). "Phosphorylated mixed isomers of L-dopa increase melanin content in skins of Skh-2 pigmented hairless mice". Pigment Cell Research. 1 (3): 137–142. doi:10.1111/j.1600-0749.1987.tb00404.x. PMID 3149738.
- ^ Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR (August 2024). "Subcutaneous Levodopa: A New Engine for the Vintage Molecule". Neurology and Therapy. 13 (4): 1055–1068. doi:10.1007/s40120-024-00635-4. PMC 11263521. PMID 38874708.
- ^ Fung VS, Aldred J, Arroyo MP, Bergquist F, Boon AJ, Bouchard M, et al. (2024). "Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance". Clinical Parkinsonism & Related Disorders. 10: 100239. doi:10.1016/j.prdoa.2024.100239. PMC 10900117. PMID 38419617.
